Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pumitamig · 7 trials · 7 indications
Phase 2
Phase 3
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 2
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| Arm A: Pumitamig | EXPERIMENTAL | - |
| Arm B: Pembrolizumab | ACTIVE_COMPARATOR | - |
| Arm C | EXPERIMENTAL | - |
| Arm D | EXPERIMENTAL | - |
| Arm A1 | EXPERIMENTAL | - |
| Arm A2 | EXPERIMENTAL | - |
| Part 1A: 1A-1 Pumitamig + Ipilimumab | EXPERIMENTAL | - |
| Part 1A: 1A-2 Pumitamig + Ipilimumab | EXPERIMENTAL | - |
| Part 1B: 1B-1 Pumitamig + Cabozantinib | EXPERIMENTAL | - |
| Part 1B: 1B-2 Pumitamig + Cabozantinib | EXPERIMENTAL | - |
| Part 2A: 2A-1 Pumitamig + Ipilimumab | EXPERIMENTAL | - |
| Part 2A: 2A-2 Pumitamig + Ipilimumab | EXPERIMENTAL | - |
| Part 2B: 2B-1 Pumitamig + Cabozantinib | EXPERIMENTAL | - |
| Part 2B: 2B-2 Pumitamig + Cabozantinib | EXPERIMENTAL | - |
| Part 2C: 2C-1 Pumitamig | EXPERIMENTAL | - |
| Part 2D: 2D-1 Pumitamig + Casdatifan | EXPERIMENTAL | - |
| Part 2E: 2E-1 Pumitamig + Ipilimumab + Casdatifan | EXPERIMENTAL | - |
| Cohort 1A | EXPERIMENTAL | - |
| Cohort 1B | EXPERIMENTAL | - |
| Cohort 2A | EXPERIMENTAL | - |
| Cohort 2B | EXPERIMENTAL | - |
| Cohort 2C | EXPERIMENTAL | - |
| Cohort 1A2 | EXPERIMENTAL | - |
| Cohort 1B2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Pumitamig | DRUG | Specified dose on specified days |
| Durvalumab | DRUG | Specified dose on specified days |
| Pembrolizumab | DRUG | Specified dose on specified days |
| Imzokitug | DRUG | Specified dose on specified days |
| Folfox | DRUG | Specified dose on specified days |
| Capox | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
| FOLFIRI | DRUG | Specified dose on specified days |
| Bevacizumab | DRUG | Specified dose on specified days |
| Ipilimumab | DRUG | Specified dose on specified days |
| Cabozantinib | DRUG | Specified dose on specified days |
| Casdatifan | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease. * Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation...
Pumitamig is an investigational oncology drug being studied for untreated, unresectable, or metastatic colorectal cancer, advanced renal cell carcinoma (RCC), locally advanced non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. It is in Phase 1 and Phase 2 clinical trials.
Pumitamig is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting multiple clinical trials evaluating the drug in various solid tumor indications.
Pumitamig is in Phase 1 and Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Active trials are recruiting participants for studies in colorectal cancer, hepatocellular carcinoma, renal cell carcinoma, and non-small cell lung cancer.
Pumitamig is being studied in several recruiting trials. NCT07221357 evaluates it with chemotherapy versus bevacizumab with chemotherapy in colorectal cancer. NCT07291076 tests it alone or with ipilimumab in HCC. NCT07293351 assesses it alone or with other agents in RCC. NCT07680764 studies it with imzokitug and chemotherapy in NSCLC.
Pumitamig is a small molecule oncology drug. Its specific molecular target has not been disclosed in the available clinical trial information. The ongoing studies are designed to evaluate its safety, tolerability, and efficacy in combination with other anticancer agents across multiple solid tumor types.
Yes, Pumitamig is being evaluated both alone and in combination with other agents. Trials include combinations with chemotherapy, ipilimumab, and imzokitug. These studies are investigating its use in first-line and advanced settings for various solid tumors including colorectal cancer, HCC, RCC, and NSCLC.